News | July 11, 2023
Briefs: Link Pharma Chem and Zydus
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Subscribe To Our Newsletter & Stay Updated
